152 results on '"Tiley, Campbell"'
Search Results
2. Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG
3. Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myeloma
4. Associations between early-life growth pattern and body size and follicular lymphoma risk and survival: a family-based case-control study
5. Supplementary Tables 1a-3d from A Population-Based Family Case–Control Study of Sun Exposure and Follicular Lymphoma Risk
6. Supplementary Figure 4 from A Population-Based Family Case–Control Study of Sun Exposure and Follicular Lymphoma Risk
7. Supplementary Figure 2 from A Population-Based Family Case–Control Study of Sun Exposure and Follicular Lymphoma Risk
8. Supplementary Figure 5 from A Population-Based Family Case–Control Study of Sun Exposure and Follicular Lymphoma Risk
9. Supplementary Figure 3 from A Population-Based Family Case–Control Study of Sun Exposure and Follicular Lymphoma Risk
10. Supplementary Figure 1 from A Population-Based Family Case–Control Study of Sun Exposure and Follicular Lymphoma Risk
11. Data from A Population-Based Family Case–Control Study of Sun Exposure and Follicular Lymphoma Risk
12. A population-based family case-control study of sun exposure and follicular lymphoma risk
13. 3178 – LONGITUDINAL DRUG INCORPORATION, CLONAL COMPOSITION, AND DNA METHYLATION DYNAMICS IN MDS/CMML PATIENTS TREATED WITH AZA
14. A Population-Based Family Case-Control Study of Sun Exposure and Follicular Lymphoma Risk.
15. Occupational exposure to extremely low-frequency magnetic fields and follicular lymphoma risk: a family case–control study
16. Dietary intake of animal-based products and likelihood of follicular lymphoma and survival: A population-based family case-control study
17. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial
18. In Vivo Drug Incorporation and Intracellular Dynamics of Injectable Versus Oral Azacytidine: A Phase II Open Label Multicentre Trial
19. Associations between Smoking and Alcohol and Follicular Lymphoma Incidence and Survival: A Family-Based Case-Control Study in Australia
20. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)
21. Promising Real World Survival Data in Adult-Onset Langerhans Cell Histiocytosis: An Australasian Lymphoma Alliance 20 Year Retrospective Study
22. Australia and New Zealand Transplant and Cellular Therapies COVID‐19 vaccination consensus position statement
23. 489 - Trends and Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study
24. Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)
25. Trends and Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study
26. Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study
27. A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis
28. Metastatic male breast cancer found from bone marrow trephine
29. A multi-center randomized controlled trial to reduce unmet needs, depression, and anxiety among hematological cancer patients and their support persons
30. In Vivo Assessment of Intracellular Dynamics Comparing Injection Versus Oral Azacitidine in a Phase IIb Investigator Initiated Clinical Trial
31. Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study
32. Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy
33. Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trial
34. The delayed diagnosis of myeloproliferative neoplasms is common and results in a high incidence of potentially preventable thrombotic complications
35. A multi-center randomized controlled trial to reduce unmet needs, depression, and anxiety among hematological cancer patients and their support persons.
36. ‘Real-world’ Australian experience of pomalidomide for relapsed and refractory myeloma
37. Raccoon eyes in systemic light chain amyloidosis
38. Lymphoma cell-of-origin assignment by gene expression profiling is clinically meaningful across broad laboratory contexts
39. Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival
40. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia
41. High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation
42. Evaluation of Pharmacokinetic-Based Dose Predictions of High Dose Melphalan in Patients with Myeloma
43. Lymphoma cell‐of–origin assignment by gene expression profiling is clinically meaningful across broad laboratory contexts.
44. Are Australian clinicians monitoring medication adherence in hematological cancer survivors? Two cross-sectional studies
45. Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.
46. Lower Drug Exposure Is Related to Renal Function and Results in Inferior Survival: A Pharmacokinetic Study of High Dose Melphalan in Myeloma
47. ‘Real-world’ Australian experience of pomalidomide for relapsed and refractory myeloma.
48. A Phase II Study of Risk-Adapted Intravenous Melphalan in Patients with AL Amyloidosis,
49. A Novel Factor V Null Mutation at Arg 506 Causes a False Positive Factor V Leiden Result
50. A Randomised Dose De-Escalation Safety Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – End of Recruitment Analysis of Response and Toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.